FOXO4-DRI
Also known as FOXO4-DRI · FOXO4-D-Retro-Inverso · Proxofim · senolytic peptide
New
Reconstitution & dosing guide
2 mg · 10 mg · 16 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only16mg x 10 vials
FOXO4-DRI · Not in current stock
$130 / vial
10mg x 10 vials
FOX04 (F410) · Not in current stock
$130 / vial
2mg x 10 vials
FOX04 (F42) · Not in current stock
$70 / vial
Prices per vial · Research use only · Not medical advice.
Synthetic D-retro-inverso peptide designed to disrupt FOXO4–p53 interaction, studied as a senolytic that selectively clears senescent cells in preclinical models.
How to picture it
Senescent ("zombie") cells stop dividing but refuse to leave, often using FOXO4 as a bodyguard that holds p53 back from ordering cleanup. FOXO4-DRI is designed as a decoy that pulls that bodyguard away so the senescent cell can enter apoptosis. Picture breaking up the meeting that keeps damaged cells hanging around — selective clearance research aimed at cells that drag tissue function down.
Research focus & benefits
- Senolytic FOXO4–p53 disruption research
- Senescent-cell clearance model studies
- Aging-biology selective apoptosis interest
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
FOXO4-DRI is a modified peptide that interferes with the FOXO4–p53 complex which helps senescent cells avoid apoptosis. Landmark mouse work showed reduced senescent-cell burden, restored fitness markers, and organ function improvements. It is one of the most discussed experimental senolytics in longevity communities, with high cost and very limited human data.
Mechanism
Blocks FOXO4 binding to p53, releasing p53 to trigger apoptosis preferentially in senescent cells that depend on FOXO4–p53 survival signaling. Designed as D-retro-inverso for protease resistance.
Research uses
- Senolytic clearance in progeroid and naturally aged mice
- Kidney function and fitness restoration models
- Senescence-associated secretory phenotype (SASP) research
Research dosing notes
Mouse studies used intermittent high-dose schedules. Community research protocols vary widely and are experimental. No approved human regimen.
Half-life / kinetics
Extended vs L-peptides due to D-amino acid design; exact human PK unknown
Common research routes
Reported considerations
- Transient inflammatory clearance effects
- Unknown long-term human safety
- High cost / purity variance across vendors
Contraindications / cautions
- Active cancer (senolytic risk theoretical)
- Pregnancy
- Frail patients without medical supervision
Common research stacks
- Dasatinib+Quercetin (different senolytic class)
- Rapamycin context
- NAD+ / mitochondrial peptides
Legal / access note
Experimental senolytic research peptide. Not approved for anti-aging use.